Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

248
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
248
Drug Therapy01:28

Drug Therapy

97
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
97
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

568
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
568
Infertility in Females01:28

Infertility in Females

401
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
401
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

750
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating the challenges of overactive bladder management in women.

World journal of urology·2026
Same author

Female sexual dysfunction: lack of change in physician practice patterns over time.

Gynecology and pelvic medicine·2026
Same author

Peripartum predictors of postpartum dyspareunia: a longitudinal observational cohort study.

Archives of women's mental health·2026
Same author

Diabetes mellitus and body weight as risk factors for de-novo urgency after trans-obturator mid-urethral sling.

European journal of obstetrics, gynecology, and reproductive biology·2025
Same author

Pelvic Organ Prolapse: Current Challenges and Future Perspectives.

Journal of clinical medicine·2025
Same author

Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta-analysis.

BJU international·2025

Related Experiment Video

Updated: Sep 10, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

174

Current and future pharmacotherapy for female sexual dysfunction.

Yacov Reisman1,2, Alexandra Dubinskaya3, Anna Padoa4,5

  • 1Sexual Medicine, Flare-Health, Amsterdam, Netherlands. uro.amsterdam@gmail.com.

Nature Reviews. Urology
|August 20, 2025
PubMed
Summary

Female sexual dysfunction (FSD) affects many women and requires a biopsychosocial approach for effective treatment. Advances include non-hormonal therapies for various FSD types, with ongoing research for future support.

More Related Videos

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

13.5K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.3K

Related Experiment Videos

Last Updated: Sep 10, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

174
Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats
09:07

Protocol for Studying Extinction of Conditioned Fear in Naturally Cycling Female Rats

Published on: February 23, 2015

13.5K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.3K

Area of Science:

  • Reproductive Medicine
  • Women's Health
  • Sexual Medicine

Background:

  • Female sexual dysfunction (FSD) is a prevalent public health concern affecting 30-50% of women.
  • Stigma, lack of awareness, and limited access to care contribute to underdiagnosis and undertreatment of FSD.
  • Significant advancements in understanding FSD have led to the development of pharmacological treatments.

Purpose of the Study:

  • To review current understanding and treatment of FSD.
  • To highlight the importance of a biopsychosocial approach in FSD management.
  • To discuss available non-hormonal pharmacological treatments for specific FSD types.

Main Methods:

  • Literature review of FSD prevalence, causes, and treatments.
  • Analysis of current pharmacological interventions for FSD.
  • Discussion of the biopsychosocial model in FSD care.

Main Results:

  • Non-hormonal pharmacological treatments are available for hypoactive sexual desire disorder, female sexual arousal disorder, female orgasmic disorder, and genitopelvic pain disorders.
  • A biopsychosocial approach is recommended for evaluating FSD treatment, considering medication, therapy, or combined methods.
  • Continued research is crucial for developing future therapies to better support women with FSD.

Conclusions:

  • FSD is a common condition necessitating comprehensive management strategies.
  • Current treatments offer options for specific FSD subtypes, emphasizing a personalized, multifaceted approach.
  • Further research and development are essential to improve outcomes for women experiencing FSD.